BioWorld

May 7, 2008

Apoptos Targeting Cell Death with $28M Series A Financing

Year-old Apoptos Inc. is raising $28 million in its first major funding round since being established in June 2007 by venture firms Venrock and ARCH Ventures based on technology targeting programmed cell death. (BioWorld Today) Read More

FDA Panel Advises Against Wider Marketing of Fentora

New Data on MedImmune, AVI BioPharma RSV Drugs

Merck Cost-Cutting Could Be Boon for Biotech Firms

Pfizer Pullout Sends NicOx Shares Down

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...